Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
November 03 2023 - 12:00PM
Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic
and synthetic biology solutions, today announced the commercial
release of its BioXp® De novo Cloning and Amplification kit on the
BioXp 3250 and BioXp 9600 systems. This cell-free DNA amplification
kit provides an efficient automated solution for building and
amplifying DNA constructs to transfection-scale quantities in
researchers’ labs by skipping tedious bacterial scale-up and
eliminating unpredictable service provider delivery times.
The new kit will provide a robust and reliable
solution to progress from sequence to functional screening in days
instead of weeks, empowering researchers in iterative discovery
applications such as antibody hit-to-lead screening and protein
engineering to streamline and control their workflow timelines.
“This new solution for cloning and amplifying
user-provided sequence to transfection scale, is an exciting new
addition to our existing family of DNA amplification kits that
enable DNA preparation for functional testing by supporting
amplification of user-provided linear or circular plasmid DNA. Now,
with the De Novo Cloning and Amplification kit, customers can go
one step further and generate amplified DNA directly from a
designed sequence. We believe the introduction of this kit further
enables researchers to overcome molecular biology workflow
bottlenecks in candidate screening with a simple solution that
provides the workflow stability, control and efficiency they need
to accelerate the path to transformational therapies.” said Todd R.
Nelson, Ph.D., CEO and Founder of Telesis Bio.
For more information on our BioXp® DNA Cloning and
Amplification Kits please visit:
https://telesisbio.com/products/bioxp-kits/dna-amplification/
About Telesis Bio Telesis Bio is
empowering scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® systems consolidate, automate,
and optimize the entire synthesis, cloning and amplification
workflow. As a result, they deliver virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson
Assembly, and BioXp are trademarks of Telesis Bio Inc.
Forward-Looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical
facts contained herein are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements include statements and
guidance regarding Telesis Bio’s future financial performance as
well as statements regarding the future release and success of new
and existing products and services. Such statements are based on
current assumptions that involve risks and uncertainties that could
cause actual outcomes and results to differ materially. These risks
and uncertainties, many of which are beyond our control, include
risks described in the section entitled Risk Factors and elsewhere
in our Quarterly Report on Form 10-Q, which was filed with the
Securities and Exchange Commission on August 11, 2023. These
forward-looking statements speak only as of the date hereof and
should not be unduly relied upon. Telesis Bio disclaims any
obligation to update these forward-looking statements.
Contact: William J. Kullback Chief Financial
Officer bill.kullback@telesisbio.com
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Aug 2023 to Aug 2024